Correction to: Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy. - OpacWWW

Tytuł:: Correction to: Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy.
Autorzy:: Langlois A; 1Department of Allergy and Immunology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC Canada.
Lavergne MH; Centre Hospitalier Sainte-Justine Research Center, Montreal, QC Canada.
Leroux H; Centre Hospitalier Sainte-Justine Research Center, Montreal, QC Canada.
Killer K; Centre Hospitalier Sainte-Justine Research Center, Montreal, QC Canada.
Azzano P; 1Department of Allergy and Immunology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC Canada.
Paradis L; 1Department of Allergy and Immunology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC Canada.; 3Department of Allergy and Immunology, Centre Hospitalier de l'Université de Montréal, 3175 Chemin de la Côte Sainte-Catherine, Montreal, QC H3T1C5 Canada.
Samaan K; 1Department of Allergy and Immunology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC Canada.
Lacombe-Barrios J; 1Department of Allergy and Immunology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC Canada.
Eiwegger T; 4Division of Immunology and Allergy, Department of Paediatrics, The Hospital for Sick Children, The University of Toronto, Toronto, ON Canada.
Upton J; 4Division of Immunology and Allergy, Department of Paediatrics, The Hospital for Sick Children, The University of Toronto, Toronto, ON Canada.
Sussman G; Gordon Sussman Clinical Research, Toronto, ON Canada.
Poder T; 6Department of Management, Evaluation and Health Policy, School of Public Health, Université de Montréal, Montreal, QC Canada.; 7Research Center of the Institut Universitaire de Santé Mentale de Montréal, Montreal, QC Canada.
Mâsse B; Centre Hospitalier Sainte-Justine Research Center, Montreal, QC Canada.; 8School of Public Health, Université de Montréal, Montreal, QC Canada.
Roches AD; 1Department of Allergy and Immunology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC Canada.; Centre Hospitalier Sainte-Justine Research Center, Montreal, QC Canada.
Bégin P; 1Department of Allergy and Immunology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC Canada.; Centre Hospitalier Sainte-Justine Research Center, Montreal, QC Canada.; 3Department of Allergy and Immunology, Centre Hospitalier de l'Université de Montréal, 3175 Chemin de la Côte Sainte-Catherine, Montreal, QC H3T1C5 Canada.
Źródło:: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology [Allergy Asthma Clin Immunol] 2020 May 20; Vol. 16, pp. 38. Date of Electronic Publication: 2020 May 20 (Print Publication: 2020).
Typ publikacji:: Published Erratum
Język:: English
Imprint Name(s):: Publication: Oct. 2009- : London : BioMed Central
Original Publication: Hamilton, Ont. : BC Decker, c2004-
References:: Allergy Asthma Clin Immunol. 2020 Apr 17;16:25. (PMID: 32328115)
Entry Date(s):: Date Created: 20200602 Latest Revision: 20220414
Update Code:: 20240104
PubMed Central ID:: PMC7240927
DOI:: 10.1186/s13223-020-00435-z
PMID:: 32477416

Pełny tekst

[This corrects the article DOI: 10.1186/s13223-020-00419-z.].
(© The Author(s) 2020.)

Erratum for: Allergy Asthma Clin Immunol. 2020 Apr 17;16:25. (PMID: 32328115)

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja

Correction to: Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy.